MarshallTSchreederMD

PubMed

• 25 citations
  Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, o...
  Jeff P. Sharman, Danielle M. Brander, Anthony R. Mato, Nilanjan Ghosh, Stephen J. Schuster, Suman Kambhampati, John M. Burke, Frederick Lansigan, Marshall T. Schreeder...> ;The Lancet. Haematology. 2021 Apr 1
• 64 citations
  Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia
  Matthew A. Lunning, Julie M. Vose, Loretta J. Nastoupil, Nathan Fowler, Jan A. Burger, William G. Wierda, Marshall T. Schreeder, Tanya Siddiqi, Christopher R. Flowers,...> ;Blood. 2019 Nov 21
• 41 citations
  Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
  Devalingam Mahalingam, Judy S. Wang, Erika Hamilton, John Sarantopoulos, John Nemunaitis, Garry Alan Weems, L. Carter, Xiao Hu, Marshall Schreeder, H. Jeffrey Wilkins> ;Clinical Cancer Research. 2019 Jun 15
• 73 citations
  Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation ...
  Loretta J. Nastoupil, Matthew A. Lunning, Julie M. Vose, Marshall T. Schreeder, Tanya Siddiqi, Christopher R. Flowers, Jonathon B. Cohen, Jan A. Burger, William G. Wie...> ;The Lancet. Haematology. 2019 Feb 1
• 11 citations
  Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia.
  Steven Coutre, Ian W. Flinn, Sven de Vos, Jacqueline C. Barrientos, Marshall T. Schreeder, Nina Wagner-Johnson, Jeff P. Sharman, Thomas E. Boyd, Nathan Fowler, Lyndah ...> ;Hemasphere. 2018 Apr 25
• 55 citations
  A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously expos...
  Ahmed Sawas, Charles M. Farber, Marshall T. Schreeder, Mazen Khalil, Daruka Mahadevan, Changchun Deng, Jennifer E Amengual, Petros Nikolinakos, Jill M. Kolesar, John G...> ;British Journal of Haematology. 2017 Apr 1
• 49 citations
  Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory ...
  Jeff P. Sharman, Charles M. Farber, Daruka Mahadevan, Marshall T. Schreeder, Heather D. Brooks, Kathryn S. Kolibaba, Suzanne R. Fanning, Leonard M. Klein, Daniel R. Gr...> ;British Journal of Haematology. 2017 Feb 1
• 14 citations
  Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma.
  Sven de Vos, Nina D. Wagner-Johnston, Steven Coutre, Ian W. Flinn, Marshall T. Schreeder, Nathan Fowler, Jeff P. Sharman, Ralph V. Boccia, Jacqueline C. Barrientos, Ka...> ;Blood Advances. 2016 Dec 13
• 70 citations
  Phase I study of single-agent CC-292, a highly selective Bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia
  Jennifer R. Brown, Wael A. Harb, Brian T. Hill, Janice Gabrilove, Jeff P. Sharman, Marshall T. Schreeder, Paul M. Barr, James M. Foran, Thomas P. Miller, Jan A. Burger...> ;Haematologica. 2016 Jul 1
• 8 citations
  Addressing the Challenge of Financial Sustainability in Biobanking.
  Antonio Campos, Marshall Schreeder, Alison Parry-Jones, Ahmed Samir Abdelhafiz, Dianna M. Larson, Barbara L. Pruetz, Timothy J. Geddes, Ayat Salman, Anthoula Lazaris> ;Biopreservation and Biobanking. 2015 Dec 23
• 96 citations
  Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
  Robert C.G. Martin, Charles R. Scoggins, Marshall T. Schreeder, William S. Rilling, Christopher J. Laing, Clifton M. Tatum, Lawrence R. Kelly, Ricardo Garcia-Monaco, V...> ;Cancer. 2015 Oct 15
• 47 citations
  Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.
  Corey J. Langer, Istvan Albert, Helen J. Ross, Peter Kovacs, L. Johnetta Blakely, Gabor Pajkos, Attila Somfay, Petr Zatloukal, Andrzej Kazarnowicz, Mehdi M. Moezi, Mar...> ;Lung Cancer. 2014 Sep 1
• 20 citations
  Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma
  Shaker R. Dakhil, Robert C. Hermann, Marshall T. Schreeder, Stephanie A. Gregory, Marc Monte, Kevin S. Windsor, Deborah Hurst, Akiko Chai, Michael Brewster, Paul Richards> ;Leukemia & Lymphoma. 2014 Jan 29
• 60 citations
  Irinotecan Drug-Eluting Beads in the Treatment of Chemo-Naive Unresectable Colorectal Liver Metastasis with Concomitant Systemic Fluorouracil and Oxaliplatin: Results ...
  Robert C.G. Martin, Charles R. Scoggins, Dana Tomalty, Marshall T. Schreeder, Tiffany Metzger, Clifton M. Tatum, Vivek R. Sharma> ;Journal of Gastrointestinal Surgery. 2012 Apr 24
• A phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110δ, in combination with anti-CD20 monoclonal antibody therapy and/or ben...
  Flinn IW, Schreeder MT, Coutre SE, Leonard J, Wagner-Johnston ND, De Vos S, Boccia RV, Holes L, Peterman S, Miller LL, Yu AS> ;J. Clin. Oncol.. 2011-05-20
• A randomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small cell lung cancer (ES-SCLC).
  Langer CJ, Albert I, Kovacs P, Blakely LJ, Pajkos G, Petrov P, Somfay A, Szczesna A, Zatloukal P, Kazarnowicz A, Moezi MM, Schreeder MT, Schnyder J, Berger MS> ;J. Clin. Oncol.. 2011-05-20
• 25 citations
  The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk o...
  David G. Hicks, Bagi R Janarthanan, Ramya Vardarajan, Swati Kulkarni, Thaer Khoury, Daniel Dim, G. Thomas Budd, Brian J. Yoder, Raymond R. Tubbs, Marshall T Schreeder,...> ;BMC Cancer. 2010 Mar 22
• A phase Ib trial of Bcl-2 inhibitor obatoclax in combination with carboplatin and etoposide for previously untreated patients with extensive-stage small cell lung canc...
  Chiappori A, Schreeder MT, Moezi MM, Stephenson J, Blakely JL, Salgia R, Chu QS, Malik SM, Modiano MM, Berger MS> ;J. Clin. Oncol.. 2009-05-20
• 72 citations
  A novel five-antibody immunohistochemical test for subclassification of lung carcinoma.
  Brian Z. Ring, Robert S. Seitz, Rodney A. Beck, William J. Shasteen, Alex Soltermann, Stefanie Arbogast, Francisco Robert, Marshall T Schreeder, Douglas T. Ross> ;Modern Pathology. 2009 May 8
• 23 citations
  TLE3 as a candidate biomarker of response to taxane therapy
  Swati Kulkarni, David G. Hicks, Nancy Watroba, Christine Murekeyisoni, Helena Hwang, Thaer Khoury, Rodney A. Beck, Brian Z. Ring, Noel C Estopinal, Marshall T Schreede...> ;Breast Cancer Research. 2009 Mar 23
• 49 citations
  Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study.
  Chandra P. Belani, Marshall T. Schreeder, Ronald G. Steis, Richard A. Guidice, Thomas A. Marsland, Elizabeth H. Butler, Suresh S. Ramalingam> ;Cancer. 2008 Nov 1
• 30 citations
  Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
  John D. Hainsworth, David R. Spigel, J. H. Barton, C. Farley, Marshall T. Schreeder, Jeremy K. Hon, F. Anthony Greco> ;Cancer. 2008 Aug 15
• Phase I report from a multicenter trial of perifosine (PERI) + sunitinib (SUT) in patients with advanced cancers including renal cell carcinoma (RCC).
  Allerton JP, Ebrahimi B, Schreeder MT, Kaiser P, Chawla SP, Sportelli P, Gardner L, Birch R, Henderson IC> ;J. Clin. Oncol.. 2008-05-20
• TLE3 as a biomarker for taxane sensitivity in breast cancer.
  Kulkarni S, Hicks DG, Watroba N, Murekeyisoni C, Beck R, Ring BZ, Estopinal N, Schreeder MT, Seitz RS, Ross DT> ;J. Clin. Oncol.. 2008-05-20
• Phase I multicenter trial of perifosine in combination with sorafenib for patients with advanced cancers including renal cell carcinoma.
  Schreeder MT, Figlin RA, Stephenson JJ, Campos L, Chawla SP, Spigel DR, Spira A, Sportelli P, Gardner L, Birch R, Henderson IC> ;J. Clin. Oncol.. 2008-05-20
• Join now to see all